cyrilzakka/clinical-trials huggingface dataset:
Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation

This is an observational cohort study of clinical efficacy study.The purpose of this topic is to evaluate the efficacy and safety of Modified Liujunzi Decoction based on syndrome differentiation in patients with chronic atrophic gastritis(CAG) after HP eradication.Taking Modified Liujunzi Decoction as the observation group and Weifuchun routine treatment as the control group, so as to provide evidence for the treatment of CAG and reduce the risk of gastric cancer. A total of 284 patients were included. The curative efficacy, symptom score and adverse events will be recorded and analyzed.


Eligibility Criteria:
Inclusion Criteria:

* Patients with CAG diagnosed by endoscopy and pathological examination, the pathological diagnosis criteria refer to the China consensus of chronic gastritis (2017) ;
* Previous HP infection, HP negative after standardized treatment;
* TCM syndrome differentiation mainly focuses on the weakness of the spleen and stomach,referring to the consensus on the diagnosis and treatment of chronic atrophic gastritis with integrated traditional Chinese and Western Medicine (2017), there is no restriction on concurrent syndrome;
* Age 18-70 years old, regardless of gender;
* The subject (or legal representative) voluntarily agreed and signed the informed consent form, and was able to abide by the study protocol during the study.

Exclusion Criteria:

* History of gastric surgery;
* Combined with serious diseases affecting the study evaluation, such as serious liver disease, heart disease, kidney disease, malignant tumor and alcoholism;
* Allergic to the drugs used in this study;
* Participated in clinical research of other drugs in the first 3 months of the study;
* Patients can't express correctly their subjective feelings and can't cooperate.
The Role of Narrow Band Imaging Videobronchoscopy in Lung Cancer

Narrow band imaging (NBI) videobronchoscopy is an optical technique in which filtered light enhances superficial neoplasm based on their neoangiogenic pattern. The objectives of this study investigate its better diagnostic yield in the assessment of lung cancer than conventional flexible bronchoscopy.

Inspection with high resolution endoscopy was followed by NBI. Detected lesions were biopsied. applied the system of shibuya et al. to analyze and classify vascular patterns by NBI into four categories (spiral and screw pattern, dotted pattern, tortuous pattern, avascular pattern) compared with the known diagnostic yield of conventional white light bronchoscopy, An equivalent or superior result will also significantly impact on patient care This technology could aid not only early-stage lung cancer diagnosis but also more accurate local staging of lung cancer.

Eligibility Criteria:
Inclusion Criteria:

* endobronchial lesion on chest CT

Exclusion Criteria:

* Age \< 18 years old
* Inability to consent for the study
* Inability to tolerate bronchoscopy
* Active pulmonary infection (bronchitis, pneumonia)
* ST elevation or depression on ECG
* Prothrombin time prolongation(\<70%)
* platelet \<10,000
COVID-19 Antibody and Reinfection Study

The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to:

1. Quantify antibody titers among participants over 9 months.
2. Determine the rates of asymptomatic, mild, and severe recurrent infection among participants with prior COVID-19.
3. Examine association between antibody titer levels and risk of recurrent infection using a case control analysis nested in the cohort.

In this study, the Kaiser Permanente Colorado (KPCO) Institute for Health Research (IHR) will evaluate SARS-CoV-2 IgG antibody titers over time among individuals with evidence of prior infection, and correlate antibody titers with risk of recurrent infection. The investigators will identify KPCO members who have and have not had prior infection, enroll them into a cohort study, conduct serial surveys for new COVID-19 symptoms, and facilitate serial viral and antibody testing.

All laboratory testing procedures and clinical management of participants will be conducted by KPCO operations. The research team will identify participants, obtain consent, administer surveys to assess COVID-19 symptoms, and direct patients to the appropriate testing. Health outcomes on cohort participants will be tracked with survey data on symptoms, clinical and utilization data from the KPCO electronic health record (e.g., hospitalization), and laboratory data (e.g., viral test results).

This research-operations partnership strategy will generate data to better understand the implications of positive antibody titers to this novel pathogen.

Eligibility Criteria:
Inclusion criteria are:

* KPCO health plan members,
* 18 years and older,
* Have a valid email address or phone number in the electronic health record.

Exclusion criterion:

• Being on the Do Not Call List for research.
Model Driven Diabetes Care

Patients with Diabetes Mellitus Type 1 using electronic self-help tools typically registers a large amount of data on their disease. The study intends to see if giving advanced feedback on these data can improve their blood glucose management.

All patients will be given access to a mobile phone with the diabetes diary known as the Few Touch Application (FTA) installed. They may use either their own compatible Android handsets, or provided handsets. The study uses a delayed start design. Participants are randomized into two groups, who get access to the module "Diastat" after 4 and 12 weeks post-enrollment respectively. Each group uses the FTA with Diastat for 8 weeks post-intervention (i.e. access to Diastat).

Diastat is a module within FTA that provides data-driven feedback to the patients using their own data. This module is based on the data recorded in a previous trial \[1\]. Three submodules are part of Diastat; Periodicity detection and visualization, multiscale trend detection based on the c-SiZer algorithm \[2\], and situation matching for insulin dosage \[3\].

1. Skrøvseth SO et al, Diabetes Technol Ther (2012)
2. Skrøvseth SO et al, PLoS ONE (2012)
3. Skrøvseth SO et al, Accepted for Advanced Technologies and Treatments for Diabetes, Paris, France, 2013.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis with Diabetes Mellitus type 1 for at least one year.
* Age over 18 years
* Has basic familiarity with mobile phones, and uses mobile phone on a daily basis.

Exclusion Criteria:

* Severe complications due to their diabetes.
* Unable to understand or conform to the guidelines when presented with the phone's software.
Exercise During the Allogeneic Stem Cell Transplantation

The study will evaluate the effects of a structured endurance exercise program on the physical performance, the mood and the complications of patients with hematological malignancies undergoing a high-dose chemotherapy followed by an allogeneic peripheral blood stem cell transplantation.


Eligibility Criteria:
Inclusion Criteria:

* Neoplastic malignancy
* Allogeneic peripheral stem cell transplantation
* Proficiency in German

Exclusion Criteria:

* Cardiorespiratory, metabolical, osteoarticular or immunological disorders which can be aggravated by exercise
* Pathological stress-ECG at admission
Investigating Severe Acute Respiratory Syndrome (SARS)

Severe Acute Respiratory Syndrome (SARS) is a newly recognized illness that can be fatal.

The purpose of this study is to better understand SARS by collecting samples of blood and other body fluids of people who have been exposed to SARS or who are suspected to have the illness.

Up to 300 volunteers aged 18 years or older will be enrolled in this study. Participants will donate blood samples and, if appropriate, samples of fluid from the lungs, nose, or throat. Researchers will test these samples for proteins that control or mediate inflammatory or immune responses. The patterns of these proteins will reveal how SARS affects the body and the efforts the body makes to fight off the infection.

Severe acute respiratory syndrome (SARS) is a newly recognized illness associated with substantial mobidity and mortality. Patients develop fever followed by rapidly progressive and even fatal respiratory disease. SARS is associated with infection with a novel coronavirus. The evaluation of the inflammatory responses evoked by SARS may yield information regarding its pathogenesis and help with patient management. This protocol, then, merely aims to study disease pathogenesis and natural history, by studying samples and data that are collected by outside physicians or physicians at the Clinical Center and sent for evaluation of the inflammatory response.

Eligibility Criteria:
* INCLUSION CRITERIA - CASES:

Patients fulfilling the CDC case definition or WHO definition for suspected or probable SARS.

Newly identified patients found to have recovered from SARS can also be enrolled.

EXCLUSION CRITERIA - CASES:

Patients diagnosed with alternative illnesses as the cause of the symptoms.

INCLUSION CRITERIA - HEALTHY VOLUNTEERS:

For the purpose of this study, a healthy volunteer is defined as a healthy male or female, age 18 and above.

Volunteers will be excluded if they have a pre-existing or concurrent serious chronic medical or psychiatric illness.

Chronic medication use will be evaluated on a case-by-case basis.

They will also be excluded if they have received an investigational drug in the past 3 months.
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.

An open-label extension study to evaluate long-term safety of eculizumab in PNH patients who had completed the TRIUMPH (C04-001), SHEPHERD (C04-002), and X03-001 studies.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have fully completed the TRIUMPH, SHEPHERD, or X03-001 studies
* TRIUMPH patients who have discontinued receiving investigational drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures
* Patient must be willing and able to give written informed consent
* Patient must avoid conception during the trial

Exclusion Criteria:

* Patients who have terminated early from the SHEPHERD or X03-001 studies
* Patients who have terminated early from the TRIUMPH study due to an adverse event
* Female who is pregnant, breast feeding, or intending to conceive during the course of the study
* Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study
Umbilical Cord Milking for Neonates With Hypoxic Ischemic Encephalopathy

The objective of this pilot study is to investigate the feasibility of performing umbilical cord milking in neonates who are depressed at birth.

Hypoxic-ischemic encephalopathy (HIE) is a brain injury in neonates due to inadequate blood flow and oxygen delivery to the neonatal brain. Umbilical cord milking can potentially improve brain injury in neonates with HIE. The objective of this study is to investigate the feasibility of performing umbilical cord milking in neonates who are depressed at birth. The investigators hypothesized that umbilical cord milking is feasible and safe in neonates who are depressed at birth. The investigators also hypothesized that umbilical cord milking will increase stem cells in neonatal blood circulation and improve short term outcomes in neonates with moderate and severe HIE.

Eligibility Criteria:
Inclusion Criteria:

* Term and near term neonates (35 weeks and more)
* Depressed at birth

Exclusion Criteria:

* Congenital malformation of central nervous system
* Chromosomal abnormalities
* Major congenital malformations
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry

Presently, multiparameter flow cytometry (MFC) and polymerase chain reaction (PCR) have been used for disease load, including measurable residual disease (MRD), monitoring in patients with myelodysplastic syndrome (MDS). MFC is the most commonly method for disease load evaluation. In patients with acute myeloid leukemia, leukemia stem cells (LSCs) determined using MFC for leukemia load and MRD detection is superior to traditional MFC method. In the investigators previous single center study, the investigators demonstrated that detection of disease load, including MRD, by MFC in patients with MDS-EB is superior to predict outcomes after allogeneic stem cell transplantation. Here, the investigators will perform a multi-center, prospective clinical trial to investigate the predictive values of MDS-SC in patients with MDS-EB who received allografting.


Eligibility Criteria:
Inclusion Criteria:

* Patients with Myelodysplastic syndromes;
* Between 15 and 70 years old;
* Subjects are able to provide written informed consent.

Exclusion Criteria:

* Subjects who cannot comply with the study;
* Patient has severe cardiac (ejection fraction \<50%), hepatic (total bilirubin \>34μmol/L, ALT, AST \>2x upper limit of normal) or renal (blood creatinine \>130μmol/L) disease；
* Uncontrolled serious infection;
* Other conditions that do not tolerate transplantation or other therapies.
Weight Regain After Consumption of Food Supplement and Interventional Diet Program

Effect of the dietary supplement (FAT-BINDER DAMM) on weight regain after 9 months of control weight program

* 60 participants will consume experimental product every day 3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner. During the 12 first weeks, each volunteer will be included on a low weight program (PPP) with an individual hypocaloric diet planning and regular physical adapted activity (PPP period). When PPP period is over, volunteers will continue consuming the product for 9 months more (Post-PPP period).
* 60 participants will consume everyday 3 placebo sticks (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner. During the first 12 weeks, each volunteer will be included on a low weight program (PPP) with an individual hypocaloric diet planning and regular physical adapted activity (PPP period ). When PPP period is over, volunteers will continue consuming the product for 9 months more.

Eligibility Criteria:
Inclusion Criteria:

* Men and women ranging from 18 to 65 years old.
* BMI ≥27 and \<40 kg/m2. Overweight type II, obesity type I and II
* Social or familiar environment that prevents from accomplishing the dietary treatment.
* Willingness to follow a balanced hypocaloric diet in order to lose weight and perform regular physical adapted activity.
* Adequate cultural level and understanding of the clinical trial.
* Signed informed consent.

Exclusion Criteria:

* Individuals diagnosed with Diabetes Mellitus type I.
* Individuals diagnosed with Diabetes Mellitus type II on pharmacological treatment.
* Individuals with dyslipidemia on pharmacological treatment.
* Individuals with hypertension on pharmacological treatment uncontrolled.
* Individuals allergic to yeast.
* Individuals with chronic diseases (hepatic, kidney...).
* Individuals who have participated in the last 6 months in a program or clinical trial to lose weight.
* Individuals receiving at least the preceding 2 months a pharmacological treatment that modifies the lipid profile (for example, statins, fibrates, diuretics, corticosteroids, ADOs).
* Pregnant or breastfeeding women.
A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population

This study aims to use a social media mini-application-enabled intervention to successfully promote the initiation and persistence of pre-exposure prophylaxis (PrEP) among at-risk people 18 years and above (including men who have sex with men (MSM), transgender women, sex workers, and other key populations) in Wuhan and Guangzhou, China.

The China National Medical Products Administration (NMPA) recently approved TDF/FTC (Truvada) for PrEP making it the first HIV prevention medicine available in China. While this is a significant step in addressing the country's rising rates of new HIV diagnoses, implementation and scale-up of this resource will be the next challenge.

3200 at-risk adults will be engaged by word of mouth and social media. Individuals will be asked to complete a survey of risk and PrEP interest, to download the study mobile mini-application onto their cell phone, and will be offered an HIV and syphilis screen. One thousand two hundred of these subjects who are eligible and willing to start PrEP will be enrolled in the study. The first 700 participants enrolled in each site will complete an additional four-phased, WeChat-based adherence intervention through a stepped-wedge design, with each cluster starting at three-month intervals.

Enrolled participants will undergo baseline laboratory testing before brought to a collaborating hospital where an established physician will provide TDF/FTC and arrange follow-up. Rural and out-of-town enrollees may undergo testing at an outside lab. All subjects will be encouraged to keep using the mini-application for receiving constant health education and counseling support on HIV/STI prevention, PrEP initiation and/or adherence management. Subjects on PrEP will be contacted every three months over the course of two years to answer questions on adherence including number of missed pills and/or sex events not covered by on-demand PrEP, adverse effect, and utilization of the mini-application. 120 enrollees in Guangdong will additionally participate in a pill count adherence sub study that counts the number of unused pills at each clinical follow-up

A PrEP messaging open contest will be organized to assess the best images and videos to enhance PrEP adherence among those who start PrEP. New content will be developed using crowdsourcing and introduced into the mini-application at staggered times. The effect of this content will be evaluated through a stepped wedge approach nested within this single arm study.

Eligibility Criteria:
Inclusion Criteria:

* Age 18+
* Engaged in at-risk sex. At risk sex is defined as sex with \>1 partner in the past 90 days, inconsistent condom use with vaginal or anal sex, ongoing sexual relationship with an HIV-positive partner, participation in commercial sex work, or any bacterial STI diagnosed or reported in the past 6 months.

Exclusion Criteria:

* History renal dysfunction
* Chronic hepatitis B (HBV) infection
* HIV infection
* Indication for HIV post-exposure prophylaxis
* Signs and symptoms consistent with acute HIV infection
* Under the age range of 18
Intrapartum Vulval and Perineal Cleansing Using Chlorhexidine Versus Normal Saline

Maternal infection during pregnancy is one of the leading causes of maternal mortality, accounting for 10.7% of maternal deaths worldwide (\~37,000 annually). Majority of maternal infection occurs during intrapartum (36%) and postpartum (47%) period, of which the genital tract is the source of infection in 89% of intrapartum and 54% of postpartum sepsis.

Introduction of skin flora into the genital tract during vaginal examination in women with rupture of membranes or active labour may cause intrapartum and puerperal sepsis. We hypothesize intrapartum vulval and perineal cleansing before vaginal examination could reduce the chance of peripartum infection caused by introducing the skin flora to intrauterine environment.

We plan to carry out a randomized controlled trial of intrapartum vulval and perineal cleansing using chlorhexidine, compared sterile water, prior to vaginal examination during labour and its effect on maternal and neonatal sepsis.


Eligibility Criteria:
Inclusion Criteria:

* All women age ≥ 18 years old
* Live singleton pregnancy
* Planned vaginal delivery
* Term in labour (after 37+0 weeks of gestation)
* Availability of GBS result at 35-37 weeks

Exclusion Criteria:

* Preterm delivery (between 24+0 to 36+6 weeks of gestation)
* Multiple pregnancy
* Presence of fever before onset of labour
* History of antibiotics use 7 days before onset of labour
* History of adverse reaction to chlorhexidine
* Planned Caesarean delivery
* Planned delivery in other units
* Women with autoimmune disease, immunodeficiency, human immunodeficiency virus or on long term steroids
* Stillbirth
* Known genital herpes
* Genital wart during pregnancy
Eye Detection to Identify Novel Coronavirus Infection

The eye characteristics of patients with COVID-19 and those without the disease were analyzed, and whether they had the disease or not was judged according to the eye characteristics.

To test the accuracy of a non-invasive eye monitoring that can be widely used for screening in judging patients with novel coronavirus infection.

Eligibility Criteria:
Inclusion Criteria:

1. All participants were provided with written informed consent at the time of recruitment；
2. Age ≥ 18 and ≤ 75 (informed consent signed by guardian under 18)
3. Meet the diagnostic criteria of novel coronavirus (2019-COVID-19) infection

Exclusion Criteria:

Does not meet any of the inclusion criteria
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation

The aim of this study is to determine if fluorescence with or without indocyanine green can facilitate safe and accurate thyroid and parathyroid surgery.

The accurate identification of the parathyroid gland is a crucial aspect of thyroid and parathyroid surgery. Failing to recognize the parathyroid gland during thyroidectomy can result in the inadvertent removal of the gland, leading to postoperative hypocalcemia. On the other hand, during parathyroidectomy, there is a risk of mistaking other structures, such as lymph nodes, for parathyroid adenomas, which can leave the patient without a cure. Currently UAB employs intraoperative PTH or radioactive isotope techniques in conjunction with surgeon judgment. However, both methods have limitations, including being time-consuming, posing logistical challenges, and not providing feedback before gland removal.

Parathyroid fluorescence is a relatively new technology. It was initially discovered that the parathyroid gland emits fluorescence, which distinguishes it from the surrounding tissues. Additionally, indocyanine green dye is readily taken up by the parathyroid gland, making its detection easy to the naked eye. Research has demonstrated that parathyroid fluorescence, with or without indocyanine green, is not only safe but also helps reduce postoperative hypocalcemia and locate lesions in patients with imaging-negative parathyroid adenomas. However, the current use of parathyroid fluorescence is not standardized, and further studies are needed to explore its clinical utility in terms of cure rates and postoperative complications.

Eligibility Criteria:
Inclusion Criteria:

* age greater than 18 years old

Exclusion Criteria:

* Patients with iodine or shellfish allergies would be excluded.
* Patients with allergy to indocyanine green.
* Pregnancy